News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS) Vaccine Division Hit by Bexsero Setback


7/24/2013 7:45:04 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Swiss drugmaker Novartis suffered a fresh blow to the turnaround prospects of its loss-making vaccines division as a key committee advised against including its meningitis B vaccine on Britain's routine vaccination program. The UK Joint Committee on Vaccination and Immunisation (JCVI) said on Wednesday that it had taken the interim decision not to recommend Bexsero because the vaccine is unlikely to prove cost-effective. Bexsero won European approval this year to become the first vaccine against "MenB", a bacterial infection that can kill in 24 hours and poses the greatest risk to infants.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at RTT News
Read at Guardian
Read at PharmaBiz

comments powered by Disqus
   
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES